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Background: Pentoxifylline (PTX) is a methylxanthine compound with immunomodulatory and antifibrotic
properties. The simultaneous use of PTX and antifungal therapy (itraconazole) has previously been evaluated in an
experimental model of pulmonary paracoccidioidomycosis (PCM), a systemic fungal disease caused by the fungus
Paracoccidioides brasiliensis (Pb) and characterized by chronic inflammation and lung fibrosis that appears even after
a successful course of antifungal therapy. The results revealed prompt and statistically significant reductions in
inflammation and fibrosis when compared to itraconazole alone. However, the effect of monotherapy with PTX on
the host response to PCM has not been well-documented. Our aim was to determine the effect of PTX on the
course of pulmonary lesions and on the local immune response.
Results: At the middle and end of treatment, the Pb-infected-PTX-treated mice exhibited significant reductions in
lung density compared to the Pb-infected-non-treated mice as assessed by the quantification of Hounsfield units
on high-resolution computed tomography (HRCT) (p <0.05 by Kruskal-Wallis test); additionally, at the end of therapy,
the lung areas involved in the inflammatory reactions were only 3 vs. 22 %, respectively, by histomorphometry
(p <0.05 by Mann–Whitney test), and this reduction was associated with a lower fungal burden and limited collagen
increment in the pulmonary lesions. PTX treatment restored the levels of IFN-γ, MIP-1β, and IL-3 that had been
down-regulated by Pb infection. Additionally, IL-12p70, IL-10, IL-13, and eotaxin were significantly increased, whereas
Regulated upon Activation, Normal T cell Expressed and Secreted (RANTES) levels were decreased in the lungs of
the Pb-infected-PTX-treated mice compared to the non-treated group.
Conclusions/significance: This study showed that PTX therapy administered at an “early” stage of granulomatous
inflammation controlled the progress of the PCM by diminishing the pulmonary inflammation and the fungal
burden and avoiding the appearance of collagen deposits in the pulmonary lesions.
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[1]. PTX reduces the production of inflammatory cyto-
kines, such as TNF, IL-1α, IL-6, and IL-8, by phagocytes
[2] and prevents their subsequent effects, such as
leukocyte adherence, migration, and degranulation [3].
Additionally, PTX has antifibrotic properties; it exerts
an antiproliferative effect on fibroblasts and inhibits
extracellular matrix synthesis [4, 5].
Because inflammation participates in the pathogen-
esis and progression of many diseases, the therapeutic
use of PTX has been studied alone or as an adjuvantrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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processes, and has produced positive effects. PTX pre-
vents murine cerebral malaria [6] and improves the prog-
nosis of this disease in humans [7, 8], decreases leukocyte
recruitment into the cerebrospinal fluid in experimental
bacterial meningitis [9], decreases organ damage, and im-
proves survival in humans [10, 11] and in animals with sep-
sis [12]. Additionally, PTX has been used simultaneously
with amphotericin-B to improve survival and to decrease
fungal burden in cerebral cryptococcosis [13].
In a previous study, we evaluated a combined PTX and
itraconazole therapy in a chronic experimental model of
paracoccidioidomycosis (PCM) [14], which is a systemic
mycosis produced by the thermally dimorphic fungus
Paracoccidioides brasiliensis (Pb) that induces granuloma-
tous inflammation and frequently progresses to pulmonary
fibrosis [14, 15]. In that study, we reported prompt reduc-
tions of pulmonary granulomatous inflammation and
fibrosis when compared to itraconazole treatment alone
[14]. However, the effect of monotherapy with PTX on the
host response to PCM has not been well-documented.
To better understand the effect of the immunomodula-
tory therapy with PTX on the course of fungal pulmonary
lesions, we used an experimental mouse model of PCM to
determine the local immune response and compared the
lungs of treated versus non-treated Pb-infected mice with
high-resolution computed tomography (HRCT), histo-
pathology/histomorphometry, and assessments of the
levels of cytokines, chemokines, and growth factors.
Results
PTX decreased the pulmonary density in the
Pb-infected mice
Before treatment (week 4), the Pb-infected mice exhib-
ited peribronchial consolidations that were associated
with a significant increase in the upper lung densities
(−263 ± 29 vs. −426 ± 68 Hounsfield units (HU) in the
control mice, p < 0.001). These increases in density were
significantly different compared to the control at all pe-
riods of evaluation (Fig. 1a, e, i). The pulmonary lesions
tended to extend to the central region of the lung, but
the increase in lung density was only higher at week 8
(Fig. 1f,j). After 4 weeks of PTX treatment (8 weeks
post-infection (p.i)), the peribronchial consolidations de-
creased and were present in 4/10 infected treated mice
(agreement between the radiologists (κ) = 0.8) in contrast
to 10/10 mice in the Pb-infected group (κ = 1.0). Al-
though multiple nodules were reported for both groups,
the agreement among the radiologists at this time was
low (κ = 0.4). At the end of therapy (12 weeks p.i),
marked differences between the groups were noticeable
(Fig. 1e,g). The infected mice continued to show the
same pattern of lesions, but they tended to be more se-
vere. Indeed, at this time, one of the infected animalsalso presented with atelectasis and another presented
with pleural thickness. In contrast, 8/10 of the mice that
were treated for 8 weeks with PTX exhibited only small
opacities that were referred to as unique nodules (Fig. 1g)
accompanied by significant overall reductions in pul-
monary density compared with the Pb-infected non-
treated mice (−451 ± 68 vs. −269 ± 25 HU; p < 0.001).
However, 4 weeks post-treatment, the pulmonary dens-
ities were reactivated in all animals (κ = 1; Fig. 1i) and
diffused bronchial dilatation was even observed.
The administration of PTX to the healthy non-infected
mice did not induce changes in the normal appearance of
the lungs or modify the pulmonary densities as expressed
in HU at any observation time (Fig. 1c,d,i,j).
PTX decreased the pulmonary inflammation area in the
Pb-infected mice
Before the beginning of the PTX treatment at 4 weeks p.i,
the Pb-infected mice presented pulmonary nodules and
evidence of incipient periarterial inflammation accompa-
nied by dispersed and intense parenchymal inflammation.
In the absence of PTX treatment, these histopathological
changes remained present and increased to reach their
greatest intensities at 8 and 12 weeks p.i. Four weeks after
the treatment onset (8 weeks p.i), the lung area occupied
by inflammatory reactions was reduced compared to the
Pb-infected group, but this difference was only statistically
significant at the end of the treatment (12 weeks) when the
average lung inflammation diminished to 3 ± 2 % vs. 22 ±
7 % in the non-treated group (p <0.05) (Fig. 2a–c). In the
middle of the therapy, PTX decreased the dispersed paren-
chymal inflammation and the cellularity at the outer re-
gions of the nodules, which prevented their confluence. At
the end of the treatment, only two nodules were observed
in five lungs (Fig. 2d–f), and only small focal areas of
periarterial inflammation composed of lymphoplasmocytic
infiltrate remained in the lungs (Fig. 2e).
PTX decreased the fungal burden in the lungs of the
Pb-infected mice
In the Pb-infected mice, the morphologies and quantities
of the fungi in the lung tissues varied depending on the
locations of the lesions and the time of the infection.
There were trends toward increases at 8 and 12 weeks
p.i. In the nodules, the fungal cells were restricted to the
central zone, and large yeasts predominated (10–20 μm;
Fig. 2g). In the perivascular lesions, the fungi were more
dispersed and frequently presented with perifungal
spaces surrounding large mother cells with multiple
small buds of less than 2 μm.
The PTX-treated mice exhibited lesser amounts of Pb
yeast in the pulmonary lesions as evidenced by pixel
counting of the stained yeast, but some small buds,
mainly in the periarterial regions, persisted (Fig. 2h,i).
Fig. 1 (See legend on next page.)
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Fig. 1 PTX treatment decreases pulmonary density in Pb-infected mice. Representative HRCT images of upper and central pulmonary regions
obtained from PBS-inoculated mice (a, b), PBS-inoculated mice treated with PTX (c, d), Pb-infected mice (e, f), and Pb-infected mice treated with
PTX (g, h) at 12 weeks. Pulmonary density was measured in the lung parenchyma as described in the “Methods” section and is expressed as the
mean of Hounsfield units (HU) ± SEM. i, j correspond to HUs measured in the upper (I) and central (J) lung regions at 0, 4, 8, 12, and 16 weeks.
The upper right symbol in (a) gives the spatial position of posterior (P), anterior (A), left (L), and right (R) regions. n = 10 mice per group at each
period of evaluation, *p <0.05; **p <0.01; ***p <0.001. ns not significant
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lesions
In the Pb-infected mice, the collagen fibers gradually in-
creased up to 12 weeks in parallel with the inflamma-
tion. The collagen depositions arranged themselves as
pseudocapsule around the nodules and were more
prominent at the periarterial lesions (Fig. 2j). Measure-
ments of the collagen pixels inside the lesions and com-
parisons between groups revealed that the PTX-treated
mice did not exhibit increases in collagen in the pul-
monary lesions while the Pb-infected untreated mice did
(Fig. 2k,l).
Immunomodulatory effect of PTX at the lung level in
healthy and Pb-infected mice
The administration of PTX to healthy non-infected mice
increased MIP1a, granulocyte-monocyte colony-stimulating
factor (GM-CSF), regulated upon activation, normal T cell
expressed and secreted (RANTES), eotaxin, IL-3, IL-4, IL-
13, and IL-10 at the middle and end of the therapy and, in
some cases, even post-therapy. Pb infection induced the
down-regulation of the immune response included reduced
expressions of some cytokines during the most chronic pe-
riods of infection (8 to 16 weeks). The cytokines included
IFN-γ, MIP-1β, TNF-α, IL-3, and IL-9. PTX treatment
restored IFN-γ, MIP-1β, and IL-3 levels to normal values
(p <0.001) (Fig. 3).
PTX therapy in Pb-infected mice also increased GM-
CSF, IL-12p70, IL-10, IL-13, and eotaxin compared to
the levels observed in the Pb-infected untreated mice.
RANTES, a chemokine that was up-regulated at all
time points post-Pb infection, was normalized to the
basal levels by PTX treatment.
In the Pb-infected mice, the pulmonary levels of IL-1α,
IL-1β, IL-2, IL-5, IL-6, IL-9, IL-12 (p40), IL-17, MIP-1α,
and TNF-α were not modified by PTX treatment
Discussion
This study showed that PTX therapy administered at an
“early” stage of granulomatous inflammation controlled
the progress of the PCM and diminished the pulmonary
inflammation and the fungal burden and prevented the
appearance of collagen deposits in the pulmonary lesions.
In this study, we applied conventional HRCT to follow
the development of the pulmonary lesions in the Pb-in-
fected mice and monitored the effects of the therapy.The results of the radiologic evaluations agreed well with
the histopathology/histomorphometry; however, in the
middle of the therapy (8 weeks p.i), the recognition of
the nodules by the radiologists exhibited minimal agree-
ment (κ = 0.4) likely because of the small sizes of the
nodules (∽400 um). The HU measurements revealed sig-
nificant decrease in lung density beginning after 4 weeks
of treatment (8 weeks p.i) despite the fact that some pul-
monary lesions (nodules) were still present at this time.
It is possible that the sizes of the nodules did not signifi-
cantly change in density in the selected regions of inter-
est (ROIs) that were larger (2000 μm in the upper and
central regions and 4000 μm in the lower lung regions).
At the end of the treatment with PTX, small infiltrates
were observed around the periarterial spaces. It would
be interesting for future studies to evaluate whether the
inflammatory cells migrated to the lymphatic vessels
around the periarterial spaces. PTX led to an improve-
ment in the immune response and reversed the im-
munosuppression observed in the Pb-infected group.
The PTX treatment restored the levels of IFN-γ that had
been down-regulated by Pb infection and increased IL-
12p70. These cytokines belong to the Th-1 profile and
are recognized for their capacity to accomplish effective
responses in PCM [16]. The level of IL-10 was higher in
the Pb-infected-PTX-treated mice than in the infected
controls, which produced high levels of IL-10 but only
until 4 weeks p.i. IL-10 is considered to be a multifaceted
anti-inflammatory cytokine [17] that helps to control in-
flammation. The up-regulation of IL-10 by methylxan-
thines such as PTX has previously been reported [18].
Interestingly, other anti-inflammatory agents, such as ste-
roids and allergen-specific immunotherapy, are also
known to elevate endogenous IL-10 levels, which may ac-
count for their efficacy [19].
The high levels of IL-10, IL-4, and IL-13 in the Pb-in-
fected-PTX-treated mice might explain the persistence
of plasmocytes in this group.
RANTES/CCL5 is a potent chemokine for T cells,
dendritic cells, eosinophils, NK cells, mast cells, and ba-
sophils [20] and is up-regulated at all times post-Pb in-
fection in this and other Pb infection models [21]. The
reduced levels of RANTES observed in the Pb-infected-
PTX-treated group might be another mechanism by
which PTX exerted its immunomodulation in this ex-
perimental model.
Fig. 2 (See legend on next page.)
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Fig. 2 PTX treatment significantly reduces pulmonary inflammation and fungal burden and hinders collagen deposition in Pb-infected treated
mice. a, d, g, j correspond to photomicrographs of lung sections of a representative Pb-infected mouse at 12 weeks p.i. stained with H&E,
Grocott, and PIFG, respectively. b, e, h, k correspond to photomicrographs of lung sections of a representative Pb-infected mouse, treated with
PTX at the end of the therapy (12 weeks p.i) stained with H&E, Grocott, and PIFG, respectively. c, f, i, l are histomorphometric quantification
graphs of inflammation, nodules, fungal burden, and collagen deposition in the pulmonary lesions of Pb-infected mice treated or not with PTX.
n = 5 mice per group at each period of evaluation, *p <0.05
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rich pulmonary micro-environment. Eotaxin is an eosino-
phil chemoattractant [22]; however, the numbers of eosin-
ophils did not increase in the lungs of the Pb-infected-
PTX-treated mice during therapy. Eosinophils appeared
after PTX release. One possible explanation is that PTX
inhibits the recruitment of cells to the inflammatory sites
as suggested by other studies [23–26]. Indeed, PTX has
been considered to be a migration-inhibiting factor for hu-
man lymphocytes, monocytes, and neutrophils [23–26]
and acts by inhibiting the adherence of these cells to the
endothelium and their transendothelial migration [27].
It has been increasingly recognized that the inflamma-
tory response and the deregulated cytokine production
play key roles in the pathogenesis of many diseases, in-
cluding certain infectious processes [28]. This study re-
inforces the idea that, in addition to itraconazole, a
second therapeutic avenue for the treatment of PCM
might be host-directed therapy with PTX [14]. Host-
directed therapy is routinely used for the management
of infectious diseases such as pediatric meningitis (corti-
costeroids and antibiotics) and hepatitis C (IFN-2b and
antivirals). However, the concept of correcting the host
responses that had been subverted by pathogen virulence
strategies has not been fully exploited [29].
Host-directed therapy has been evaluated in experi-
mental PCM. The immunosuppressor cyclophosphamide
has been used to modulate immune responses to Pb in
rats infected with Pb yeasts via the intracardiac route
[30, 31]. This study reported that treated rats presented
with the following: a) a decrease in granuloma size and
granulomas with fewer fungal cells, b) a lack of specific
antibodies, and c) a significant increase in the paracocci-
dioidin footpad swelling test (delayed-type hypersensitiv-
ity (DTH)). In another study [32], resistant (A/Sn) and
susceptible (B10.A) mice were treated with either a low
dose of cyclophosphamide or indomethacin, which is a
potent inhibitor of prostaglandin synthesis. In the A/Sn
mice, the cyclophosphamide induced a recovery of the
IgE anti-ovalbumin antibody (OA) antibody response. In
the B10.A mice, this effect was extended to IgG1, IgG2a,
and total levels of anti-OA antibodies. In general, these
studies suggested that “the suppressive stages” in PCM,
such as the lack of specific antibodies and DTH, could
be inhibited by some immunomodulators such as cyclo-
phosphamide and indomethacin. Indeed, in the presentstudy, we observed that PTX hindered the immune
down-regulation induced by Pb during the infection’s
natural course.
PTX has been studied in other fungal infections previ-
ously. Ostrosky-Zeichner et al. [13] reported on the effects
of pentoxifylline or dexamethasone alone or in combin-
ation with amphotericin-B in experimental mouse cerebral
cryptococcosis. The amphotericin-B plus pentoxifylline-
treated mice exhibited survived for significantly longer
and exhibited decreased fungal burdens in the brain than
the mice in the other treated groups [13]. However, in an-
other study, PTX at 20 mg/kg every 8 h had no effect on
experimental systemic Candida albicans infection, but
higher doses of 30 and 60 mg/kg of pentoxifylline every
8 h increased fungal counts in kidneys when compared to
the controls [33]. In this last study, the authors used doses
that were higher than we employed and administered
PTX by intraperitoneal injection, which likely induced an
immunosuppressive state.
Granulomas are a hallmark of PCM and tuberculosis and
have traditionally been thought to restrict mycobacterial
growth. However, analysis of Mycobacterium marinum in
zebrafish has shown that early granulomas facilitate myco-
bacterial growth. Uninfected macrophages are recruited to
the granuloma where they are productively infected by M.
marinum to facilitate the disease progress [32]. We believe
that a similar situation might occur with Pb.
The antifibrogenic effect of PTX that was also observed
in this study has been attributed to both the inhibition of
extracellular matrix (ECM)-producing cell proliferation
and the reduction in the deposition of ECM components,
primarily collagen type I, by producer cells [4, 34–37].
The use of PTX apparently caused a paradoxical situ-
ation, i.e., simultaneous decreases in the inflammatory
reaction and the number of fungi. If PTX induces inhibi-
tions of peripheral blood mononuclear cells, endothelial
production of IL-8 and monocyte chemotactic protein-1
(MCP-1), leucocyte chemotaxis and diapedesis, endothe-
lial adhesion molecule expression, T/NK cell cytotoxicity
and cytokine production and apoptosis pathways, and
the Fas ligand (FasL or CD95L) [4, 34–37], it should be
expected to increase the fungal load. However, the op-
posite was observed. This phenomenon is more puzzling
if we consider the possible direct effect of PTX on the
fungi; i.e., the inhibition of the Pb phosphodiesterase
and the consequent increase in intracellular cyclical
Fig. 3 Effects of PTX on pulmonary cytokine levels in healthy and Pb-infected mice. The 21 evaluated molecules were grouped into five
categories according to their primary functions: a pro-inflammatory cytokines, b chemokines and growth factors, c Th-1 cytokines, d Th-2
cytokines, and e cytokines with regulatory functions. All molecules were measured in PBS-inoculated mice (white bars); PBS-inoculated mice,
treated with PTX (gray bars); Pb-infected mice (black bars); and Pb-infected mice, treated with PTX (striped bars). The graphs show three periods
of evaluation corresponding to the middle of the treatment, end of the treatment, and 4 weeks post-treatment (8, 12, and 16 weeks p.i.,
respectively). The experimental groups were compared using two-way ANOVA with Tukey’s multiple comparison test. The bars show the mean ±
SEM. *p <0.05, **p <0.001, ***p <0.0001. n = 5 mice per group at each period of evaluation
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mycelium to yeast [4, 34–37].
This paradox raises the hypothesis of a possible effect
of the inflammatory reaction and its products on fungal
viability or a direct and unknown effect of PTX on P.
brasiliensis; in the first sense and since IFN-γ plays an
important role both on the immune response by themodulation of some activities of macrophages and T and
B cells and on the host resistance against several pathogens
including P. brasiliensis [16, 38, 39], it is possible that the
increased IFN-γ levels observed in Pb-infected-PTX-treated
mice could have triggered an effective immune response in-
ducing the elimination of P. brasiliensis. In the second
sense, some reports have shown that methylxanthines have
Lopera et al. Fibrogenesis & Tissue Repair  (2015) 8:10 Page 8 of 11antifungal properties related to the inhibition of fungal chit-
inases [40, 41]. More specifically, Cryptococcus neoformans
and Aspergillus fumigatus treated with pentoxifylline exhib-
ited abnormal cell morphology. In addition, pentoxifylline-
treated C. neoformans showed increased susceptibility to
calcofluor and a leaky melanin phenotype consistent with
defective cell wall function [40]. Unfortunately, no direct
experiments in this sense have been made with P.
brasiliensis.
Although we found a positive PTX effect on the
course of pulmonary lesions in Pb-infected mice, our
study has some limitations. We focused exclusively on
the lungs and other organs which were not included in
our study, the evaluation of fungal dissemination, the
characterization of the IFN-γ-producing cells, and the
treatment of infected IFN-γ knockout mice with PTX to
determine whether PTX combats P. brasiliensis via the
intermediacy of IFN-γ-mediated processes are worthy to
be conducted in future studies.
Conclusions
In conclusion, this study showed that Pb infection can
be positively modulated by anti-inflammatory therapy




All animals were handled according to the Colombian
national (Law 84 of 1989, Res No. 8430 of 1993) and
international (Council of European Communities and
Canadian Council of Animal Care, 1998) guidelines for
animal research. Additionally, the experimental proto-
cols were approved by the research ethics committee of
the Corporación para Investigaciones Biológicas (CIB).
Mice and experimental groups
BALB/c mice were originally obtained from Taconic
Farms, Inc. Quality Laboratory Animals and Services for
Research, New York, USA, and the breeding colony was
later expanded at the CIB, Medellin, Colombia. The mice
were divided into four groups: (A) non-infected or control
(n = 50), (B) infected with 3 × 106 Pb conidia (n = 50), (C)
non-infected-PTX-treated mice (n = 30), and (D) Pb-in-
fected-PTX-treated mice (n = 30).
Fungus and experimental infection
Pb isolate ATCC-60855 from a Colombian patient regis-
tered at the American Type Culture (Rockville, MD,
USA) and known to produce abundant conidia was used
in all experiments [42]. Pb conidia were produced and
collected as previously described [42–44].
Seven-week-old male mice weighing approximately 20 g
were anesthetized by intramuscular injection of a solutioncontaining ketamine hydrochloride (Park, Davis &
Company, Berlin, Germany; 100 mg/kg) and xylazine
(Bayer, Brazil; 10 mg/kg) [45]. When deep anesthesia was
obtained, 3 × 106 Pb viable conidia (in 0.06 ml of the inocu-
lum) were intranasally (i.n) instilled. Control mice received
an intranasal inoculum of 0.06 ml of PBS.
Pentoxifylline treatment
Pentoxifylline (P1784 Sigma-Aldrich, St. Louis, MO,
USA) was provided at a dose of 20 mg/kg in 10 μl of so-
lution. This concentration had been previously used in a
mouse model of cryptococcosis [13]. Treatment began
4 weeks p.i when the granulomatous inflammation had
begun and continued daily for 8 weeks.
Evaluation periods
PBS-inoculated and Pb-infected mice were evaluated at
0 (2 h), 4, 8, 12, and 16 weeks post-infection. The PTX-
treated mice were analyzed during therapy (at 8 and
12 weeks p.i) and 4 weeks post-treatment (at 16 weeks
p.i). The chests of ten mice from each group were
scanned by HRCT at each period of observation (see
section 2.6). Then, the mice were sacrificed by intra-
peritoneal injection of 1.0 ml of 2.5 % sodium pento-
thal (Sandoz Laboratories, Kundl, Austria), and their
lungs were removed and assigned for further testing in
histopathological (five mice) and immunological (five
mice) studies.
High-resolution CT
The thoraxes of the mice were scanned as previously
published by our group [46]. Briefly, the mice were
anesthetized with ketamine hydrochloride and xylazine
and placed in the prone position inside polypropylene
tubes (50 ml) that were arranged together in a wood box
with parallel holes. All of the animals were placed with
their noses in the same vertical plane. Each animal had a
code for future identification. The box containing the mice
was then placed in the CT gantry for thorax scanning.
CT images were taken in a multislice CT-scanner
(General Electric, EU) with 16 canals by applying
140 kV at 165 mAs/s (Kernel U90). Thin-section slices,
each 0.625 mm thick and spaced 1 mm apart, covered
the complete mouse lung from the apex to the hemi-
diaphragm. Images were acquired in the axial plane,
and the bone algorithm was applied to better visualize
the lung. The field of view was 18 cm to simultan-
eously include all of the animals with a matrix of 512 ×
512 and an acquisition time of one second per section.
Approximately 20 to 22 slices covered the entire lung.
Following the scan, the mice were placed in their cages
to recover from the anesthesia for 35 min. The animals
were supplied with standard laboratory diet and water
ad libitum.
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The image analysis was performed independently and
blindly by two radiologists from the Radiology Department
of the University Hospital San Vicente de Paul (Medellín,
Colombia). The images were visualized using an Advantage
workstation version 4.3 (General Electric) via the lung and
mediastinal windows.
The pulmonary densities were evaluated as described
by Plathow et al. [47] with some modifications [46]. Rep-
resentative tomographic slides were used to calculate the
HU. Briefly, eight ROIs were selected in the following
areas of the right and left lungs: the upper or hilar re-
gion (approximately 5 slides below the apex, where the
main bronchi enter the lungs), the anterior and posterior
middle or central region (approximately 12 slides below
the apex where the heart presents its largest diameter),
and the lower lung region (approximately 18 slides bel-
low the apex, corresponding to the bases of the lungs).
These circles were 2 mm2 for the upper and middle re-
gions and 4 mm2 for the lower regions.
Histopathological analysis
After scanning, five animals per group at each period of
evaluation were killed by thiopental overdose (Sandoz
GmbH., Kundl, Austria; 1 ml at 2.5 %, i.p.) in accordance
with animal ethical practices. The lungs of the mice were
intracardially perfused with 10 % neutral formalin in
phosphate-buffered saline, removed, and fixed in the
same solution for at least 48 h. The fixed lungs were em-
bedded in paraffin, and coronal sections (4 μm) were
stained with the following methods: hematoxylin-eosin
(HE) for evaluation of the lung histology and inflamma-
tion, Grocott’s methenamine-silver nitrate technique
(Grocott) for identification of the fungi, picrosirius with
fast green (PIFG) for identification of I and III interstitial
collagens [48], Lennert’s Giemsa for lymphocyte and
plasma cell recognition [49], sirius red (pH 10.2) for cel-
lular characterization and eosinophil identification [50,
51], and Masson’s trichrome for the collagen fibers and
the recognition of the Mott cells that correspond to ab-
normal plasma cells, and are characterized by the pres-
ence of globular cytoplasmic inclusions that are
composed of immunoglobulins.
The cellular compositions were evaluated blinded by a
pathologist using a semi-quantitative approach. Scores
of (−) to (+++) were given according to the degree of in-
filtration as follows: (+++) for intense, (++) for moder-
ate, (+) for slight, (±) for very slight, and (−) for no
reaction [52].
Quantitative image analysis
The H&E-, Grocott- and PIFG-stained slides were auto-
matically scanned with a ScanScope® CS (Aperio, Vista,
CA, USA) at 20X and also analyzed with an AxioObserver.Z1 (Zeiss) coupled with digital camera with
AxioCam HRc and software AxioVision 4.7.2 (Zeiss).
The lung inflammatory areas were measured based on
one panoramic image of both lungs per mouse. The im-
ages were analyzed with the free ImageScope software
(http://www.aperio.com/download-imagescope-viewer.-
asp). The areas of interest (AOIs) corresponding to the
inflammatory regions were manually drawn and mea-
sured. The percentage of pulmonary area exhibiting an
inflammatory reaction was calculated by dividing the
sum of the total of the AOIs by the total area occupied
by the lung tissue (excluding the air space).
The Aperio positive pixel count algorithm was used to
quantify the amount of a specific stain present in a scan
slide image. Red pixels in the PIFG-stained slides were
measured to quantify collagen, and brown/black pixels
in the Grocott’s-stained slides were measured to quantify
the glucans present in the fungal wall. The results are
expressed as the sum of strong-, medium- and weak-
positive pixels in the total area measured.
Cytokines, chemokines, and growth factor detection by
multiplex micro-bead immunoassay
The lungs of five animals per group were individually ho-
mogenized in a tissue grinder (Tissue tearor, model 985–
370, Biospec Products) with a cocktail solution of protease
inhibitors (pepsin 0.1 μM, leupeptin 0.1 μM, phenylmethyl
sulfonide fluoride 1 mM, N-tosyl-L-phenylalanine chloro-
methyl ketone 0.2 mM, (a)-p-methyl L-lysine chloromethyl
ketone 0.1 mM from Sigma chemical, plus ethylene-
diamine-tetraacetic acid (EDTA) 1 nM from Merck
Germany). The homogenized lung supernatants were col-
lected by centrifugation at 3000 rpm for 15 min at 4 °C, ali-
quoted, and stored at −70 °C until the day of analysis.
All homogenized lung supernatants were normalized
to 1 mg/ml of protein. Then, a magnetic bead-based
multiplex assay containing fluorescent-dyed micro-
spheres conjugated with a monoclonal antibody specific
for a target protein was used for cytokines, chemokines,
and growth factor measurements according to the man-
ufacturer’s instructions (Bio-Plex pro-mouse cytokine
21-plex assay; Bio-Rad Inc., Hercules, CA, USA). The
following molecules were measured: IL1-α, IL-1β, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12
(p70), IL-13, IL-17, eotaxin, GM-CSF, IFN-γ, monocyte
chemoattractive protein (MCP-1/CCL2), macrophage in-
flammatory protein alpha and beta (MIP-1α/CCL3 and
MIP-1β/CCL4), RANTES (CCL5), and TNF-α.
The levels of each molecule were determined in duplicate
with the multiplex array reader of the Luminex™ Instru-
mentation System (Bio-Plex Workstation from Bio-Rad La-
boratories). The analyte concentrations were calculated
using software provided by the manufacturer (Bio-Plex
Manager Software) and are expressed as pg/ml.
Lopera et al. Fibrogenesis & Tissue Repair  (2015) 8:10 Page 10 of 11Statistical analyses
The statistical analyses were performed with Prism 5.0
software (GraphPad, San Diego, CA, USA). Non-
parametric Kruskal-Wallis tests with Dunn’s post tests
were used to compare the selected groups. The values
are expressed as medians with interquartile ranges.
p values under 0.05 were considered statistically signifi-
cant. The kappa (κ) coefficient was used as a statistical
measure of agreement between the two radiologists.
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